3,333
Participants
Start Date
July 31, 2012
Primary Completion Date
February 28, 2014
Study Completion Date
December 31, 2015
SEQureDx Trisomy Test
Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
Medical University of South Carolina, Charleston
Magnolia OB/GYN Research Center- Recruiting, Myrtle Beach
Providence Health Partners - Center for Clinical Research, Dayton
William Beaumont Hospital, Royal Oak
Spectrum Health - Maternal Fetal Medicine, Grand Rapids
University of Iowa Health Care, Iowa City
University of Kansas Medical Center, Kansas City
University of Oklahoma Health Sciences Center, Oklahoma City
Precision Trials, Phoenix
New Horizon Women's Care, Chandler
Visions Clinical Research Tuscon, Tucson
Fair Oaks Women's Health, Pasadena
Descanso OBGYN, Glendale
Woodglen Medical Group, Glendora
White Memorial GYN/OB Medical Group, Los Angeles
Women's Clinical Research, Vista
IGO Medical Group, San Diego
West Coast OBGYN, San Diego
Women's Health Care Research, San Diego
Hawaii Pacific Health, Honolulu
University of South Alabama, Mobile
Virtua Health, Moorestown
Virtua Health, Mount Holly
Jersey Shore University Medical Center, Neptune City
Saint Peter's Hospital, New Brunswick
Virtua Health, Sewell
Virtua Health, Voorhees Township
Sequenom, Inc.
INDUSTRY